RT Journal Article
SR Electronic
T1 Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.29.22274477
DO 10.1101/2022.04.29.22274477
A1 Khan, Khadija
A1 Karim, Farina
A1 Ganga, Yashica
A1 Bernstein, Mallory
A1 Jule, Zesuliwe
A1 Reedoy, Kajal
A1 Cele, Sandile
A1 Lustig, Gila
A1 Amoako, Daniel
A1 Wolter, Nicole
A1 Samsunder, Natasha
A1 Sivro, Aida
A1 San, James Emmanuel
A1 Giandhari, Jennifer
A1 Tegally, Houriiyah
A1 Pillay, Sureshnee
A1 Naidoo, Yeshnee
A1 Mazibuko, Matilda
A1 Miya, Yoliswa
A1 Ngcobo, Nokuthula
A1 Manickchund, Nithendra
A1 Magula, Nombulelo
A1 Karim, Quarraisha Abdool
A1 von Gottberg, Anne
A1 Abdool Karim, Salim S.
A1 Hanekom, Willem
A1 Gosnell, Bernadett I.
A1 ,
A1 Lessells, Richard J.
A1 de Oliveira, Tulio
A1 Moosa, Mahomed-Yunus S.
A1 Sigal, Alex
YR 2022
UL http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274477.abstract
AB The SARS-CoV-2 Omicron (B.1.1.529) variant first emerged as the BA.1 sub-lineage, with extensive escape from neutralizing immunity elicited by previous infection with other variants, vaccines, or combinations of both1,2. Two new sub-lineages, BA.4 and BA.5, are now emerging in South Africa with changes relative to BA.1, including L452R and F486V mutations in the spike receptor binding domain. We isolated live BA.4 and BA.5 viruses and tested them against neutralizing immunity elicited to BA.1 infection in participants who were Omicron/BA.1 infected but unvaccinated (n=24) and participants vaccinated with Pfizer BNT162b2 or Johnson and Johnson Ad26.CoV.2S with breakthrough Omicron/BA.1 infection (n=15). In unvaccinated individuals, FRNT50, the inverse of the dilution for 50% neutralization, declined from 275 for BA.1 to 36 for BA.4 and 37 for BA.5, a 7.6 and 7.5-fold drop, respectively. In vaccinated BA.1 breakthroughs, FRNT50 declined from 507 for BA.1 to 158 for BA.4 (3.2-fold) and 198 for BA.5 (2.6-fold). Absolute BA.4 and BA.5 neutralization levels were about 5-fold higher in this group versus unvaccinated BA.1 infected participants. The observed escape of BA.4 and BA.5 from BA.1 elicited immunity is more moderate than of BA.1 against previous immunity1,3. However, the low absolute neutralization levels for BA.4 and BA.5, particularly in the unvaccinated group, are unlikely to protect well against symptomatic infection4.This may indicate that, based on neutralization escape, BA.4 and BA.5 have potential to result in a new infection wave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council Award 6084COAP2020 (AS)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study at the Africa Health Research Institute approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). The Omicron/BA.1 and BA.4 was isolated from a residual swab sample with SARS-CoV-2 isolation from the sample approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M210752). The sample to isolate Omicron/BA.5 was collected after written informed consent as part of the COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care Centre for the AIDS Programme of Research in South Africa (CAPRISA) study and approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001195/2020, BREC/00003106/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences of outgrown Omicron sub-lineages have been deposited in GISAID with accession EPI_ISL_7886688 (Omicron/BA.1), EPI_ISL_12268495.2 (Omicron/BA.4), EPI_ISL_12268493.2 (Omicron/BA.5). Raw images of the data are available upon reasonable request.